Dulaglutide as an Fc fusion — what changes analytically?

This matters because it predicts what a related molecule should do.

These are treated as interchangeable and I do not think they are.

If both are acceptable I would like to know that, so I can stop thinking about it.

Is there a defensible reason to prefer one, or is this a coin flip?

Start with the architecture: fusion protein rather than acylated peptide, which is why it is much larger and why its clearance behaves differently.

The IgG4 Fc is modified to reduce effector function and to prevent half-antibody exchange, which is standard practice for therapeutic Fc fusions and matters for immunogenicity.

Reconciling gross mass to label claim

Concretely, weight reduction is modest — of the order of two to four kilograms at the higher doses — which is a genuine difference from the acylated agents rather than an artefact of comparison.

Fc fusion as a half-life extension strategy is well established across therapeutic proteins and works through FcRn-mediated recycling.

REWIND for outcomes, AWARD for glycaemia.

Put another way, this agent is the clearest illustration in the class that there is more than one way to solve the half-life problem.

That manufacturing difference is why research-grade "dulaglutide" is a much more dubious proposition than research-grade acylated peptides: the molecule is not something solid-phase peptide synthesis produces.

More usefully, being a fusion protein, it is manufactured in cell culture rather than by solid-phase synthesis, which puts it in a different category from every other agent discussed on this site.

The molecule is produced by recombinant expression, not by chemical synthesis, which is a fact worth checking any supplier claim against.

Five-day half-life, weekly dosing, four strengths.

edited 17 Jul 2026 by dana_wexler — updated for the 2026 guidance change

Answering this needs the trial name: REWIND for cardiovascular outcomes and the AWARD programme for glycaemia.

Elimination half-life is about five days, supporting weekly dosing, with licensed strengths of 0.75, 1.5, 3.0 and 4.5 mg.

It helps to be literal here: immunogenicity is a live consideration for a fusion protein in a way it is not for a 31-residue acylated peptide, and anti-drug antibody rates are reported in the trial programme accordingly.

REWIND is the cardiovascular outcome trial; the AWARD programme covers glycaemic efficacy across comparators.

Fc fusion, not acylation. That is the structural fact that explains the rest.

It helps to be literal here: REWIND is worth knowing about specifically because its population had a lower baseline cardiovascular risk than most outcome trials in the class.

REWIND randomised a type 2 diabetes population in which a majority did not have established cardiovascular disease, so its result speaks more to primary prevention than most trials in the class.

Cross-trial weight comparisons against acylated agents are confounded by dose and population.

Weight-modest and glycaemically strong, consistently across the programme.

Answer first: a GLP-1 analogue fused to a modified immunoglobulin Fc fragment, which is a completely different half-life strategy from the acylated peptides.

The molecule is two GLP-1 analogue peptides linked to a modified human IgG4 Fc fragment. Half-life extension comes from neonatal Fc receptor recycling, which rescues the protein from lysosomal degradation, rather than from albumin binding.

IgG4 Fc modifications to prevent Fab-arm exchange are standard and are documented in the primary characterisation literature for this molecule.

Research-use material is not approved for human use.

Recombinant expression, not solid-phase synthesis. Read supplier claims accordingly.